BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
PFE upcoming catalysts
Pfizer: 10 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (7 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 26 readout(s) and 7 FDA event(s). Subscribe to PFE (.ics).
Drugs: Ritlecitinib, RSVpreF, VLA15, Fulvestrant, Encorafenib, Pembrolizumab, Pomalidomide, Dexamethasone, Rimegepant, Ritlecitinib higher, Ritlecitinib lower, Vepdegestrant, Palbociclib, Letrozole, PF-07104091 escalation, PF-07104091 expansion, Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, Binimetinib, Ribociclib, Elotuzumab, Bortezomib, Carfilzomib, Cetuximab, Glofitamab, Obinutuzumab, Daratumumab, enzalutamide
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-29 est. | P3 | Pfizer PFE | NCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | Menstrual Migraine | recruiting | 723 |
| 2026-12-02 est. | P3 | Pfizer PFE | NCT07029711 A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | Severe Alopecia Areata | active not recruiting | 208 |
| 2026-12-04 est. | P3 | Pfizer PFE | NCT07500506 A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | Lyme Disease | recruiting | 1712 |
| 2026-12-08 est. | P2 | Pfizer PFE | NCT07228390 A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradeniti | Hidradenitis Suppurativa | active not recruiting | 128 |
| 2026-12-25 est. | P2 | Pfizer PFE | NCT07219615 A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | Chronic Spontaneous Urticaria | recruiting | 200 |
| 2026-12-30 est. | P3 | Pfizer PFE | NCT05909397 Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | Breast Cancer | active not recruiting | 59 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2026-12-31 est. | P3 | Pfizer PFE | NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors | active not recruiting | 77 |
| 2027-01-18 est. | P3 | Pfizer PFE | NCT05035212 Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | Lower Respiratory Tract Illness | active not recruiting | 38861 |
| 2027-01-25 est. | P3 | Pfizer PFE | NCT07653100 A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF | Respiratory Syncytial Virus (RSV) | recruiting | 540 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-10-26 | FDA approval | approved | PFIZER PFE | TALZENNA | Approved 2026-10-26: TALZENNA (NDA217439 SUPPL4) |
| 2026-10-26 | FDA approval | approved | PFIZER PFE | TALZENNA | Approved 2026-10-26: TALZENNA (NDA211651 SUPPL14) |
| 2026-06-24 | FDA approval | approved | PFIZER PFE | IBRANCE | Approved 2026-06-24: IBRANCE (NDA207103 SUPPL24) |
| 2026-06-24 | FDA approval | approved | PFIZER PFE | IBRANCE | Approved 2026-06-24: IBRANCE (NDA212436 SUPPL12) |
| 2026-06-05 | FDA approval | approved | PFIZER INC PFE | HYMPAVZI | Approved 2026-06-05: HYMPAVZI (BLA761369 SUPPL3) |
| 2026-03-06 | FDA approval | approved | PFIZER PFE | XELJANZ | Approved 2026-03-06: XELJANZ (NDA213082 SUPPL13) |
| 2026-03-06 | FDA approval | approved | PFIZER PFE | XELJANZ | Approved 2026-03-06: XELJANZ XR (NDA208246 SUPPL27) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-12 est. | P2 | Pfizer PFE | NCT05995964 A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 507 |
| 2026-10-30 est. | P3 | Pfizer PFE | NCT04657991 A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Melanoma | active not recruiting | 257 |
| 2026-10-09 | P2 | Pfizer PFE | NCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Stu | Pulmonary Hypertension | terminated | 42 |
| 2026-10-06 | P1/P2 | Pfizer PFE | NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-St | Breast Cancer | terminated | 20 |
| 2026-09-29 | P1/P2 | Pfizer PFE | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | Obesity and Obesity-related Medical Conditions | completed | 201 |
| 2026-09-23 | P2 | Pfizer PFE | NCT05070845 Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | terminated | 61 |
| 2026-09-10 | P1/P2 | Pfizer PFE | NCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-S | Breast Cancer | terminated | 11 |
| 2026-08-26 | P3 | Pfizer PFE | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatment | Multiple Myeloma | recruiting | 492 |
| 2026-08-25 | P3 | Pfizer PFE | NCT07543380 A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. | Respiratory Syncytial Virus (RSV) | completed | 130 |
| 2026-07-31 | P1/P2 | Pfizer PFE | NCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | completed | 97 |
| 2026-07-30 est. | P3 | Pfizer PFE | NCT05261139 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Ho | COVID-19 | recruiting | 160 |
| 2026-07-23 | P2 | Pfizer PFE | NCT03307980 Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B | Hemophilia B | terminated | 21 |
| 2026-06-19 | P2 | Pfizer PFE | NCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorecta | Metastatic Colorectal Cancer | active not recruiting | 108 |
| 2026-05-12 | P1/P2 | Pfizer PFE | NCT06182124 A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults | Pneumococcal Disease | completed | 1710 |
| 2026-04-09 | P1/P2 | Pfizer PFE | NCT05896163 A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory | Diffuse Large B-Cell Lymphoma | terminated | 40 |
| 2026-02-26 | P3 | Pfizer PFE | NCT05020236 A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Multiple Myeloma | recruiting | 893 |
| 2026-02-18 | P3 | Pfizer PFE | NCT04821622 Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Prostate Cancer | active not recruiting | 599 |
| 2026-02-09 | P2 | Pfizer PFE | NCT06531538 A Study to Learn About How a New Pneumococcal Vaccine Works in Children | Pneumococcal Disease | completed | 225 |
| 2026-02-05 | P3 | Pfizer PFE | NCT05583526 A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | completed | 607 |
| 2026-02-02 | P2 | Pfizer PFE | NCT05926960 A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | Melanoma | terminated | 38 |
| 2026-01-12 | P2 | Pfizer PFE | NCT06105632 A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Br | Advanced or Metastatic Breast Cancer | active not recruiting | 333 |
| 2026-01-07 | P3 | Pfizer PFE | NCT05477524 An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) | Lyme Disease | completed | 12546 |
| 2025-12-29 | P2 | Pfizer PFE | NCT06897202 A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM | Obesity in Diabetes; Type 2 Diabetes Mellitus (T2DM) | completed | 133 |
| 2025-12-22 | P3 | Pfizer PFE | NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Derm | Dermatitis, Atopic | completed | 3166 |
| 2025-12-16 | P2 | Pfizer PFE | NCT06973720 A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight | Obesity; Overweight or Obesity | completed | 268 |
| 2025-12-16 | P2 | Pfizer PFE | NCT04821310 Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years | Esophagitis | terminated | 43 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.